Annual Drug Patent Expirations for TASIGNA
Tasigna is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in TASIGNA is nilotinib hydrochloride. One supplier is listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com